SEC Form 4 · accession 0001179110-17-014584
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kate Haviland
Officer — Chief Business Officer
Period of report
Nov 21, 2017
Accepted (ET)
Nov 22, 2017 · 5:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2017 | M | 5,874 | $16.28 | A | 5,874 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $16.28 | Nov 21, 2017 | M | 5,874 | D | — | Feb 1, 2026 | Common Stock | 5,874 | 95,985 | D |
Explanation of responses
- F1This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.